Volume 67, Issue 4, Pages (April 2015)

Slides:

Advertisements

Similar presentations

Volume 60, Issue 5, Pages (November 2011)

Advertisements

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 4, Pages (October 2010)

Volume 57, Issue 1, Pages (January 2010)

European Urology Oncology

Volume 72, Issue 5, Pages (November 2017)

Histologic Grading of Noninvasive Papillary Urothelial Neoplasms

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 68, Issue 1, Pages (July 2015)

Volume 72, Issue 5, Pages (November 2017)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 52, Issue 1, Pages (July 2007)

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 51, Issue 1, Pages (January 2007)

Volume 61, Issue 5, Pages (May 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 59, Issue 4, Pages (April 2011)

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 1, Pages (July 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 59, Issue 4, Pages (April 2011)

Volume 69, Issue 4, Pages (April 2016)

Volume 64, Issue 3, Pages (September 2013)

Volume 67, Issue 3, Pages (March 2015)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 5, Pages (May 2012)

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 6, Pages (December 2011)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 66, Issue 2, Pages (August 2014)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 53, Issue 1, Pages (January 2008)

Volume 62, Issue 3, Pages (September 2012)

Volume 15, Issue 4, Pages (April 2014)

Volume 50, Issue 5, Pages (November 2006)

Volume 67, Issue 6, Pages (June 2015)

Volume 15, Issue 1, Pages (January 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 72, Issue 5, Pages (November 2017)

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

Volume 70, Issue 1, Pages (July 2016)

European Urology is “Your” Journal

Volume 52, Issue 4, Pages (October 2007)

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

European Urology Oncology

Volume 67, Issue 3, Pages (March 2015)

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Volume 76, Issue 1, Pages (July 2019)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

Volume 67, Issue 4, Pages 599-602 (April 2015) SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma Thomas Geldart, John Chester, Angela Casbard, Simon Crabb, Tony Elliott, Andrew Protheroe, Robert A. Huddart, Graham Mead, Jim Barber, Robert J. Jones, Joanna Smith, Robert Cowles, Jessica Evans, Gareth Griffiths European Urology Volume 67, Issue 4, Pages 599-602 (April 2015) DOI: 10.1016/j.eururo.2014.11.003 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 (A) Progression-free survival, (B) overall survival (OS), and (C) OS by Bajorin prognostic group. European Urology 2015 67, 599-602DOI: (10.1016/j.eururo.2014.11.003) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Relative dose intensity (actual dose intensity divided by expected dose intensity) by cycle and treatment. RDI=relative dose intensity. European Urology 2015 67, 599-602DOI: (10.1016/j.eururo.2014.11.003) Copyright © 2014 European Association of Urology Terms and Conditions